Base de dados : MEDLINE
Pesquisa : D03.383.742.698.875.842.455 [Categoria DeCS]
Referências encontradas : 543 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 55 ir para página                         

  1 / 543 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26239884
[Au] Autor:Kwak S; Ku SK; Kang H; Baek MC; Bae JS
[Ad] Endereço:College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 702-701, Republic of Korea.
[Ti] Título:Methylthiouracil, a new treatment option for sepsis.
[So] Source:Vascul Pharmacol;88:1-10, 2017 Jan.
[Is] ISSN:1879-3649
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The screening of bioactive compound libraries can be an effective approach for repositioning FDA-approved drugs or discovering new treatments for human diseases. Inhibition of high mobility group box 1 (HMGB1) and restoration of endothelial integrity are emerging as an attractive therapeutic strategies in the management of severe sepsis or septic shock. Here, we examined the effects of methylthiouracil (MTU), used as antithyroid drug, by monitoring the effects on lipopolysaccharide (LPS)- or cecal ligation and puncture (CLP)-mediated release of HMGB1, and on the modulation of HMGB1-mediated inflammatory responses. The anti-inflammatory activities of MTU were determined by measuring permeability, leukocyte adhesion and migration, and the activation of pro-inflammatory proteins in HMGB1-activated HUVECs and mice. MTU inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses in human endothelial cells. MTU also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in mice. In addition, treatment with MTU reduced CLP-induced release of HMGB1 and sepsis-related mortality and pulmonary injury. Our results indicate that MTUs could be candidate therapeutic agents for various severe vascular inflammatory diseases via the inhibition of the HMGB1 signaling pathway.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Proteína HMGB1/metabolismo
Metiltiouracila/farmacologia
Sepse/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Movimento Celular/efeitos dos fármacos
Modelos Animais de Doenças
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Inflamação/tratamento farmacológico
Inflamação/patologia
Leucócitos/metabolismo
Lipopolissacarídeos/toxicidade
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Sepse/patologia
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (HMGB1 Protein); 0 (Lipopolysaccharides); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150805
[St] Status:MEDLINE


  2 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27421058
[Au] Autor:Min G; Ku SK; Jeong S; Baek MC; Bae JS
[Ad] Endereço:College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, BK21 Plus KNU Multi-Omics based Creative Drug Research Team, Kyungpook National University, Daegu, Korea.
[Ti] Título:Suppressive effects of methylthiouracil on polyphosphate-mediated vascular inflammatory responses.
[So] Source:J Cell Mol Med;20(12):2333-2340, 2016 Dec.
[Is] ISSN:1582-4934
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Drug repositioning is used to discover drug candidates to treat human diseases, through the application of drugs or compounds that are approved for the treatment of other diseases. This method can significantly reduce the time required and cost of discovering new drug candidates for human diseases. Previous studies have reported pro-inflammatory responses of endothelial cells to the release of polyphosphate (PolyP). In this study, we examined the anti-inflammatory responses and mechanisms of methylthiouracil (MTU), which is an antithyroid drug, and its effects on PolyP-induced septic activities in human umbilical vein endothelial cells (HUVECs) and mice. The survival rates, septic biomarker levels, behaviour of human neutrophils and vascular permeability were determined in PolyP-activated HUVECs and mice. MTU suppressed the PolyP-mediated vascular barrier permeability, up-regulation of inflammatory biomarkers, adhesion/migration of leucocytes, and activation and/or production of nuclear factor-κB, tumour necrosis factor-α and interleukin-6. Furthermore, MTU demonstrated protective effects on PolyP-mediated lethal death and the levels of the related septic biomarkers. Therefore, these results indicated the therapeutic potential of MTU on various systemic inflammatory diseases, such as sepsis or septic shock.
[Mh] Termos MeSH primário: Vasos Sanguíneos/patologia
Inflamação/induzido quimicamente
Inflamação/tratamento farmacológico
Metiltiouracila/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Vasos Sanguíneos/efeitos dos fármacos
Permeabilidade Capilar/efeitos dos fármacos
Adesão Celular/efeitos dos fármacos
Moléculas de Adesão Celular/metabolismo
Movimento Celular/efeitos dos fármacos
Modelos Animais de Doenças
MAP Quinases Reguladas por Sinal Extracelular/metabolismo
Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana/metabolismo
Células Endoteliais da Veia Umbilical Humana/patologia
Inflamação/patologia
Interleucina-6/biossíntese
Metiltiouracila/química
Metiltiouracila/farmacologia
Camundongos Endogâmicos C57BL
NF-kappa B/metabolismo
Neutrófilos/citologia
Neutrófilos/efeitos dos fármacos
Polifosfatos
Substâncias Protetoras/farmacologia
Substâncias Protetoras/uso terapêutico
Fator de Necrose Tumoral alfa/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell Adhesion Molecules); 0 (Interleukin-6); 0 (NF-kappa B); 0 (Polyphosphates); 0 (Protective Agents); 0 (Tumor Necrosis Factor-alpha); EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160716
[St] Status:MEDLINE
[do] DOI:10.1111/jcmm.12925


  3 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26298005
[Au] Autor:Ku SK; Baek MC; Bae JS
[Ad] Endereço:Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, Gyeongsan 712-715, Republic of Korea.
[Ti] Título:Anti-inflammatory effects of methylthiouracil in vitro and in vivo.
[So] Source:Toxicol Appl Pharmacol;288(3):374-86, 2015 Nov 01.
[Is] ISSN:1096-0333
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The screening of bioactive compound libraries can be an effective approach for repositioning FDA-approved drugs or discovering new treatments for human diseases. Here, methylthiouracil (MTU), an antithyroid drug, was examined for its effects on lipopolysaccharide (LPS)-mediated vascular inflammatory responses. The anti-inflammatory activities of MTU were determined by measuring permeability, human neutrophil adhesion and migration, and activation of pro-inflammatory proteins in LPS-activated human umbilical vein endothelial cells and mice. We found that post-treatment with MTU inhibited LPS-induced barrier disruption, expression of cell adhesion molecules (CAMs), and adhesion/transendothelial migration of human neutrophils to human endothelial cells. MTU induced potent inhibition of LPS-induced endothelial cell protein C receptor (EPCR) shedding. It also suppressed LPS-induced hyperpermeability and neutrophil migration in vivo. Furthermore, MTU suppressed the production of tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, and the activation of nuclear factor-κB (NF-κB) and extracellular regulated kinases (ERK) 1/2 by LPS. Moreover, post-treatment with MTU resulted in reduced LPS-induced lethal endotoxemia. These results suggest that MTU exerts anti-inflammatory effects by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Moléculas de Adesão Celular/metabolismo
Metiltiouracila/farmacologia
Neutrófilos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antígenos CD/genética
Antígenos CD/metabolismo
Antitireóideos/farmacologia
Adesão Celular/efeitos dos fármacos
Movimento Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Receptor de Proteína C Endotelial
Endotoxemia/tratamento farmacológico
Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana/metabolismo
Seres Humanos
Interleucina-6/metabolismo
Lipopolissacarídeos/efeitos adversos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Proteína Quinase 1 Ativada por Mitógeno/genética
Proteína Quinase 1 Ativada por Mitógeno/metabolismo
Proteína Quinase 3 Ativada por Mitógeno/genética
Proteína Quinase 3 Ativada por Mitógeno/metabolismo
NF-kappa B/metabolismo
Neutrófilos/metabolismo
Receptores de Superfície Celular/genética
Receptores de Superfície Celular/metabolismo
Receptor 4 Toll-Like/genética
Receptor 4 Toll-Like/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antigens, CD); 0 (Antithyroid Agents); 0 (Cell Adhesion Molecules); 0 (Endothelial Protein C Receptor); 0 (Interleukin-6); 0 (Lipopolysaccharides); 0 (NF-kappa B); 0 (PROCR protein, human); 0 (Receptors, Cell Surface); 0 (TLR4 protein, human); 0 (Toll-Like Receptor 4); 0 (Tumor Necrosis Factor-alpha); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150823
[St] Status:MEDLINE


  4 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26117428
[Au] Autor:Baek MC; Jung B; Kang H; Lee HS; Bae JS
[Ad] Endereço:Department of Molecular Medicine, CMRI, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea.
[Ti] Título:Novel insight into drug repositioning: Methylthiouracil as a case in point.
[So] Source:Pharmacol Res;99:185-93, 2015 Sep.
[Is] ISSN:1096-1186
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Drug repositioning refers to the development of existing drugs for new indications. These drugs may have (I) failed to show efficacy in late stage clinical trials without safety issues; (II) stalled in the development for commercial reasons; (III) passed the point of patent expiry; or (IV) are being explored in new geographic markets. Over the past decade, pressure on the pharmaceutical industry caused by the 'innovation gap' owing to rising development costs and stagnant product output have become major reasons for the growing interest in drug repositioning. Companies that offer a variety of broad platforms for identifying new indications have emerged; some have been successful in building their own pipelines of candidates with reduced risks and timelines associated with further clinical development. The business models and platforms offered by these companies will be validated if they are able to generate positive proof-of-concept clinical data for their repositioned compounds. This review describes the strategy of biomarker-guided repositioning of chemotherapeutic drugs for inflammation therapy, considering the repositioning of methylthiouracil (MTU), an antithyroid drug, as a potential anti-inflammatory reagent.
[Mh] Termos MeSH primário: Reposicionamento de Medicamentos/métodos
Metiltiouracila/farmacologia
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/farmacologia
Antitireóideos/farmacologia
Artrite Reumatoide/tratamento farmacológico
Biomarcadores/análise
Doxiciclina/farmacologia
Descoberta de Drogas
Reposicionamento de Medicamentos/tendências
Eritema Nodoso/tratamento farmacológico
MAP Quinases Reguladas por Sinal Extracelular/antagonistas & inibidores
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Propriedade Intelectual
Hanseníase Virchowiana/tratamento farmacológico
Periodontite/tratamento farmacológico
Fosfolipases A2 Secretórias/antagonistas & inibidores
Talidomida/farmacologia
Vasculite/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antithyroid Agents); 0 (Biomarkers); 4Z8R6ORS6L (Thalidomide); EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases); EC 3.1.1.4 (Phospholipases A2, Secretory); N12000U13O (Doxycycline); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150910
[Lr] Data última revisão:
150910
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150629
[St] Status:MEDLINE


  5 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26043683
[Au] Autor:Jung B; Ku SK; Bae JS
[Ad] Endereço:College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 702-701 Republic of Korea.
[Ti] Título:Ameliorative effect of methylthiouracil on TGFBIp-induced septic responses.
[So] Source:Biochem Biophys Res Commun;463(4):661-6, 2015 Aug 07.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The screening of bioactive compound libraries can be an effective approach for repositioning FDA-approved drugs or discovering new treatments for human diseases. Transforming growth factor ß-induced protein (TGFBIp) is an extracellular matrix protein whose expression in several cell types is greatly increased by TGF-ß. TGFBIp is released by human umbilical vein endothelial cells (HUVECs), and functions as a mediator of experimental sepsis. Here, we investigated the anti-septic effects and underlying mechanisms of methylthiouracil (MTU), used as antithyroid drug, against TGFBIp-mediated septic responses in HUVECs and mice. The anti-inflammatory activities of MTU were determined by measuring permeability, human neutrophils adhesion and migration, and activation of pro-inflammatory proteins in TGFBIp-activated HUVECs and mice. According to the results, MTU effectively inhibited lipopolysaccharide-induced release of TGFBIp, and suppressed TGFBIp-mediated septic responses, such as hyperpermeability, adhesion and migration of leukocytes, and expression of cell adhesion molecules. In addition, MTU suppressed CLP-induced sepsis lethality and pulmonary injury. Collectively, these results indicate that MTU could be a potential therapeutic agent for treatment of various severe vascular inflammatory diseases via inhibition of the TGFBIp signaling pathway.
[Mh] Termos MeSH primário: Antitireóideos/farmacologia
Proteínas da Matriz Extracelular/fisiologia
Metiltiouracila/farmacologia
Sepse/prevenção & controle
Fator de Crescimento Transformador beta/fisiologia
[Mh] Termos MeSH secundário: Animais
Adesão Celular/efeitos dos fármacos
Movimento Celular/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Masculino
Camundongos
Neutrófilos/citologia
Neutrófilos/efeitos dos fármacos
Sepse/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antithyroid Agents); 0 (Extracellular Matrix Proteins); 0 (Transforming Growth Factor beta); 148710-76-3 (betaIG-H3 protein); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:150708
[Lr] Data última revisão:
150708
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150606
[St] Status:MEDLINE


  6 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19774650
[Au] Autor:Chernov'yants MS; Dolinkin AO; Chernyshev AV; Khohlov EV; Golovanova EG
[Ad] Endereço:Department of Analytical Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia. chernov@rsu.ru
[Ti] Título:Interaction of antithyroid drugs with bovine serum albumin: electrophoretic and fluorimetric study.
[So] Source:J Pharm Sci;99(3):1567-73, 2010 Mar.
[Is] ISSN:1520-6017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The pre-equilibrium capillary zone electrophoretic (pre-eq CZE) method to determine association constants of active anionic forms of antithyroid drugs: 6-n-propyl-2-thiouracil (PTU), 6-methyl-2-thiouracil (MTU), 2-thiouracil (TU) with bovine serum albumin (BSA) under physiological pH 7.4 has been developed for the first time. Using the decrease of the selective electrochromatographic peak area of a drug anionic form due to binding with BSA the association constants K of the binary BSA complexes were calculated. It has been found that the binding constants (log K) of BSA with TU, MTU, and PTU are equal to 2.99, 1.85, and 2.11, respectively. The interaction of PTU, MTU, TU, 2-mercapto-1-methylimidazole (MMI), and ethyl-3-methyl-2-thionoimidazoline-1-carboxylate (Carb), which is considered to be a prodrug for MMI, with BSA has been investigated under physiological conditions by means of fluorescence spectroscopy. Fluorescence emission spectra of BSA in the presence of thioamides recorded at 295 nm excitation wavelength clearly show that the studied drugs act as quenchers, except MMI, which acts as quencher when being excited at 280 nm. The 295 nm light excites tryptophan residues, while the 280 nm light excites both tryptophan and tyrosine residues. The binding constants (log K) of BSA with PTU, MTU, TU, MMI, and Carb have been found to be 4.51, 4.30, 4.30, 2.64, and 4.32, respectively.
[Mh] Termos MeSH primário: Antitireóideos/farmacocinética
Eletroforese Capilar/métodos
Fluorometria/métodos
Soroalbumina Bovina/metabolismo
[Mh] Termos MeSH secundário: Técnicas In Vitro
Metiltiouracila/farmacocinética
Propiltiouracila/farmacocinética
Ligação Proteica
Tiouracila/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antithyroid Agents); 27432CM55Q (Serum Albumin, Bovine); 59X161SCYL (Thiouracil); 721M9407IY (Propylthiouracil); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:1004
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090924
[St] Status:MEDLINE
[do] DOI:10.1002/jps.21915


  7 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19286005
[Au] Autor:Vanden Bussche J; Noppe H; Verheyden K; Wille K; Pinel G; Le Bizec B; De Brabander HF
[Ad] Endereço:Ghent University, Faculty of Veterinary Medicine, Research Group of Veterinary Public Health and Zoonoses, Laboratory Chemical Analysis, Salisburylaan 133, B-9820 Merelbeke, Belgium.
[Ti] Título:Analysis of thyreostats: a history of 35 years.
[So] Source:Anal Chim Acta;637(1-2):2-12, 2009 Apr 01.
[Is] ISSN:1873-4324
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Thyreostatic drugs (TS), illegally administrated to livestock for fattening purposes, are banned in the European Union since 1981 (Council Directive 81/602/EC). This paper reviews the trends in the analytical approaches for the determination of TS drugs in biological matrices. After a brief introduction on the different groups of compounds with a thyreostatic action, the most relevant legislation regarding the residue control of these compounds is presented. An overview of the analytical possibilities for the determination of TS in animal matrices, covering sample extraction, purification, separation techniques and detection methods is provided. Additionally, a brief outline of animal experiments is described that illustrates the excretion and distribution profiles of TS residues. Finally, the novel developments in TS analysis are highlighted. Also the possible semi-endogenous status of thiouracil is discussed.
[Mh] Termos MeSH primário: Antitireóideos/história
[Mh] Termos MeSH secundário: Animais
Antitireóideos/análise
Antitireóideos/isolamento & purificação
Bovinos
Cromatografia Gasosa
Cromatografia Líquida de Alta Pressão
História do Século XX
História do Século XXI
Compostos Inorgânicos/análise
Metiltiouracila/análise
Oxazolidinonas/análise
Espectrometria de Massas por Ionização por Electrospray
Suínos
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antithyroid Agents); 0 (Inorganic Chemicals); 0 (Oxazolidinones); 7Q618OJ6K9 (goitrin); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:0906
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090317
[St] Status:MEDLINE
[do] DOI:10.1016/j.aca.2008.08.027


  8 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17521973
[Au] Autor:Wei Y; Zhang ZJ; Zhang YT; Sun YH
[Ad] Endereço:Department of Chemistry, Shaanxi Normal University, Xi'an 710062, China. weiyue_2005@hotmail.com
[Ti] Título:Determination of propylthiouracil and methylthiouracil in human serum using high-performance liquid chromatography with chemiluminescence detection.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;854(1-2):239-44, 2007 Jul 01.
[Is] ISSN:1570-0232
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Based on the sensitizing effect of formaldehyde on the chemiluminescence (CL) reaction of propylthiouracil (PTU) and methylthiouracil (MTU) with acidic potassium permanganate and the combination technique of high-performance liquid chromatography (HPLC), a sensitive, selective and simple post-column CL detection method for determining PTU and MTU is described. The optimal conditions for the CL detection and HPLC separation were carried out. The linear ranges were 0.1-20 microg mL(-1) for MTU and 0.1-10 microg mL(-1) for PTU, the detection limits were 0.03 microg mL(-1) for PTU, 0.03 microg mL(-1) for MTU and the quantification limits were 0.1 microg mL(-1) for PTU, 0.1 microg mL(-1) for MTU. The method has been satisfactorily applied for the determination of MTU and PTU in human serum samples.
[Mh] Termos MeSH primário: Antitireóideos/sangue
Cromatografia Líquida de Alta Pressão/métodos
Metiltiouracila/sangue
Propiltiouracila/sangue
[Mh] Termos MeSH secundário: Calibragem
Seres Humanos
Cinética
Luminescência
Padrões de Referência
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Antithyroid Agents); 721M9407IY (Propylthiouracil); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:0710
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:070525
[St] Status:MEDLINE


  9 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15941032
[Au] Autor:Zhang L; Liu Y; Xie MX; Qiu YM
[Ad] Endereço:Analytical & Testing Center of Beijing Normal University, Xinjiekowaidajie 19, Beijing 100875, China.
[Ti] Título:Simultaneous determination of thyreostatic residues in animal tissues by matrix solid-phase dispersion and gas chromatography-mass spectrometry.
[So] Source:J Chromatogr A;1074(1-2):1-7, 2005 May 13.
[Is] ISSN:0021-9673
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A method for determination of thyreostatic residues in animal tissues by matrix solid-phase dispersion (MSPD) and gas chromatography-mass spectrometry in selected ion detection mode was developed. Thyreostatic compounds in different matrices were extracted and purified by combination of MSPD and subsequent solid-phase extraction. Silica gel was selected as the solid support of both procedures and the conditions of the procedures were optimized. Thyreostats were derivatized with pentafluorobenzylbromide (PFBBr) in strong basic medium and then with N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA), which can improve the yields of derivatization for thyreostats, the repeatability, and therefore the limits of detection (LOD) of thyreostats. The limits of detection reached 10 microg/kg (2-thiouracil, 6-methyl-2-thiouracil and 6-propyl-2-thiouracil), 20 microg/kg (6-phenyl-2-thiouracil) and 50 microg/kg (tapazole) with high recoveries (more than 70% for most of thyreostats) and relative standard deviations between 4.5% and 8.7%.
[Mh] Termos MeSH primário: Antitireóideos/análise
Fluoracetatos
[Mh] Termos MeSH secundário: Acetamidas
Animais
Antitireóideos/isolamento & purificação
Fluorbenzenos
Cromatografia Gasosa-Espectrometria de Massas/métodos
Metimazol/isolamento & purificação
Metiltiouracila/isolamento & purificação
Propiltiouracila/isolamento & purificação
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Sílica Gel
Dióxido de Silício
Suínos
Tiouracila/isolamento & purificação
Compostos de Trimetilsilil
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acetamides); 0 (Antithyroid Agents); 0 (Fluoroacetates); 0 (Fluorobenzenes); 0 (Trimethylsilyl Compounds); 1765-40-8 (pentafluorobenzyl bromide); 24589-78-4 (N-methyl-N-(trimethylsilyl)trifluoroacetamide); 554Z48XN5E (Methimazole); 59X161SCYL (Thiouracil); 60650-90-0 (Silica Gel); 721M9407IY (Propylthiouracil); 7631-86-9 (Silicon Dioxide); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:0508
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050609
[St] Status:MEDLINE


  10 / 543 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:15718400
[Au] Autor:Ratajczak P; Oliviéro P; Marotte F; Kolar F; Ostadal B; Samuel JL
[Ad] Endereço:CRCIL U689, IFR139, Hôpital Lariboisière, 41 Boulevard de la Chapelle, 75475 Paris Cedex 10, France.
[Ti] Título:Expression and localization of caveolins during postnatal development in rat heart: implication of thyroid hormone.
[So] Source:J Appl Physiol (1985);99(1):244-51, 2005 Jul.
[Is] ISSN:8750-7587
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Caveolins modulate signaling pathways involved in cardiac development. Caveolin-1 exists in two isoforms: the beta-isoform derivates from an alternative translational start site that creates a protein truncated by 31 amino acids, mainly expressed in endothelial cells, whereas caveolin-3 is present in muscle cells. Our aim was to define caveolin distribution and expression during cardiac postnatal development using immunofluorescence and Western blotting. Caveolin-3 sarcolemmal labeling appeared as dotted lines from days 1 to 5 and as continuous lines after 14 days of age. Caveolin-3 expression, low at birth, increased (4-fold) to reach a maximum (P < 0.05) by day 5 and then decreased to stabilize in adults. Total caveolin-1 and its alpha-isoform were codistributed at birth in endothelial and smooth muscle cells; afterward, only the caveolin-1alpha labeling became limited to endothelium. Quantitative analysis indicated a similar temporal pattern of both total caveolin-1 and caveolin-1alpha expression, suggesting that caveolin-1alpha and -1beta are coregulated; the caveolin-1alpha levels increased fourfold by day 5 to reach a maximum by day 14 (P < 0.05). Tyrosine-14-caveolin-1 phosphorylation, low at birth, increased suddenly around day 14 (8-fold vs. day 1) and returning afterward to basal level. Because the T3/T4 level is maximal by day 14, caveolin-1 expression/phosphorylation profiles were analyzed in hypothyroid heart. The levels of caveolin-1alpha and consequently tyrosine-14-caveolin-1 phosphorylation, but not that of caveolin-3, decreased (50%) in hypothyroid 14-day-old rats. Our data demonstrate that, during postnatal cardiac growth, 1) caveolins are distinctly regulated, and 2) thyroid hormones are involved in caveolin-1alpha expression.
[Mh] Termos MeSH primário: Envelhecimento/metabolismo
Caveolinas/metabolismo
Coração/crescimento & desenvolvimento
Hipotireoidismo/metabolismo
Miocárdio/metabolismo
Hormônios Tireóideos/metabolismo
[Mh] Termos MeSH secundário: Adaptação Fisiológica
Animais
Animais Recém-Nascidos
Regulação da Expressão Gênica
Coração/embriologia
Hipotireoidismo/induzido quimicamente
Hipotireoidismo/embriologia
Metiltiouracila
Ratos
Ratos Wistar
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Caveolins); 0 (Thyroid Hormones); QW24888U5F (Methylthiouracil)
[Em] Mês de entrada:0509
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050219
[St] Status:MEDLINE



página 1 de 55 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde